Siegel R.L. Miller K.D. Fuchs H.E. et al.

Cancer statistics, 2022.

CA A Cancer J Clin. 72: 7-33Akdogan B. Gudeloglu A. Inci K. et al.

Prevalence and predictors of benign lesions in renal masses smaller than 7 cm presumed to be renal cell carcinoma.

Clin Genitourin Cancer. 10: 121-125

Cancer of the Kidney and Renal Pelvis - Cancer Stat Facts. SEER.

() ()Deschavanne P.J. Fertil B.

A review of human cell radiosensitivity in vitro.

Int J Radiat Oncol Biol Phys. 34: 251-266

Proceedings: Carcinoma of the kidney.

Cancer. 32: 1056-1061

The Value of Radiotherapy in the Treatment of Hypernephroma-a Clinical Trial.

Br J Urol. 45: 258-269Kjaer M. Iversen P. Hvidt V. et al.

A Randomized Trial of Postoperative Radiotherapy Versus Observation in Stage II and III Renal Adenocarcinoma.

Scand J Urol Nephrol. 21: 285-289Tunio M.A. Hashmi A. Rafi M.

Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials.

Ann Oncol. 21: 1839-1845Ning S. Trisler K. Wessels B.W. et al.

Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts.

Cancer. 80: 2519-2528Walsh L. Stanfield J.L. Cho L.C. et al.

Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model.

Eur Urol. 50 (): 795-800Garcia-Barros M. Paris F. Cordon-Cardo C. et al.

Tumor response to radiotherapy regulated by endothelial cell apoptosis.

Science. 300: 1155-1159Marathe S. Schissel S.L. Yellin M.J. et al.

Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling.

J Biol Chem. 273: 4081-4088Song C.W. Glatstein E. Marks L.B. et al.

Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): Indirect Cell Death.

Int J Radiat Oncol Biol Phys. 110: 21-34Sonier M. Chu W. Lalani N. et al.

Evaluation of kidney motion and target localization in abdominal SBRT patients.

J Appl Clin Med Phys. 17: 429-433Yamamoto T. Kawasaki Y. Umezawa R. et al.

Stereotactic body radiotherapy for kidney cancer: a 10-year experience from a single institute.

J Radiat Res. 62: 533-539Motzer R.J. Escudier B. McDermott D.F. et al.

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

N Engl J Med. 373: 1803-1813Motzer R.J. Tannir N.M. McDermott D.F. et al.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

N Engl J Med. 378: 1277-1290Rini B.I. Plimack E.R. Stus V. et al.

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

N Engl J Med. 380: 1116-1127Garnett C.T. Palena C. Chakraborty M. et al.

Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes.

Cancer Res. 64: 7985-7994Kachikwu E.L. Iwamoto K.S. Liao Y.P. et al.

Radiation Enhances Regulatory T Cell Representation.

Int J Radiat Oncol Biol Phys. 81: 1128-1135Teitz-Tennenbaum S. Li Q. Okuyama R. et al.

Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy.

J Immunother. 31: 345-358Wersäll P.J. Blomgren H. Pisa P. et al.

Regression of nonirradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma.

Acta Oncol. 45: 493-497Deng L. Liang H. Burnette B. et al.

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice.

J Clin Invest. 124: 687-695Park S.S. Dong H. Liu X. et al.

PD-1 Restrains Radiotherapy-Induced Abscopal Effect.

Cancer Immunol Res. 3: 610-619Masini C. Iotti C. De Giorgi U. et al.

Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.

Eur Urol. 81: 274-282Siva S. Bressel M. Wood S.T. et al.

Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.

Eur Urol. 81: 364-372McBride S. Sherman E. Tsai C.J. et al.

Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.

J Clin Oncol. 39: 30-37Ljungberg B. Albiges L. Abu-Ghanem Y. et al.

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update.

Eur Urol. 82: 399-410Campbell S.C. Clark P.E. Chang S.S. et al.

Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I.

J Urol. 206: 199-208Leibovich B.C. Blute M.L. Cheville J.C. et al.

Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy.

J Urol. 171: 1066-1070Van Poppel H. Da Pozzo L. Albrecht W. et al.

A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.

Eur Urol. 59: 543-552Huang W.C. Levey A.S. Serio A.M. et al.

Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study.

Lancet Oncol. 7: 735-740Kopp R.P. Mehrazin R. Palazzi K.L. et al.

Survival outcomes after radical and partial nephrectomy for clinical T2 renal tumours categorised by R.E.N.A.L. nephrometry score.

BJU Int. 114: 708-718Crispen P.L. Breau R.H. Allmer C. et al.

Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates.

Eur Urol. 59: 18-23Blom J.H.M. van Poppel H. Maréchal J.M. et al.

Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881.

Eur Urol. 55: 28-34Gore J.L. Kim H.L. Schulam P.

Initial experience with laparoscopically assisted percutaneous cryotherapy of renal tumors.

J Endourol. 19: 480-483Clark T.W.I. Malkowicz B. Stavropoulos S.W. et al.

Radiofrequency ablation of small renal cell carcinomas using multitined expandable electrodes: preliminary experience.

J Vasc Interv Radiol. 17: 513-519Bandi G. Wen C.C. Hedican S.P. et al.

Cryoablation of small renal masses: assessment of the outcome at one institution.

BJU Int. 100: 798-801Zagoria R.J. Traver M.A. Werle D.M. et al.

Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas.

AJR Am J Roentgenol. 189: 429-436Klatte T. Mauermann J. Heinz-Peer G. et al.

Perioperative, Oncologic, and Functional Outcomes of Laparoscopic Renal Cryoablation and Open Partial Nephrectomy: A Matched Pair Analysis.

J Endourol. 25: 991-997

A critical analysis of surgery for kidney cancer with vena cava invasion.

Eur Urol. 52: 658-662Haas N.B. Manola J. Uzzo R.G. et al.

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Lancet. 387: 2008-2016Ravaud A. Motzer R.J. Pandha H.S. et al.

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

N Engl J Med. 375: 2246-2254Motzer R.J. Haas N.B. Donskov F. et al.

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

J Clin Oncol. 35: 3916-3923Choueiri T.K. Tomczak P. Park S.H. et al.

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

N Engl J Med. 385: 683-694Motzer R.J. Jonasch E. Agarwal N. et al.

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Cancer Netw. 20: 71-90

Complications of image-guided radiofrequency ablation of renal cell carcinoma: causes, imaging features and prevention methods.

Eur Radiol. 19: 2180-2190Hegarty N.J. Gill I.S. Desai M.M. et al.

Probe-ablative nephron-sparing surgery: Cryoablation versus radiofrequency ablation.

Urology. 68: 7-13Atwell T.D. Carter R.E. Schmit G.D. et al.

Complications following 573 Percutaneous Renal Radiofrequency and Cryoablation Procedures.

J Vasc Interv Radiol. 23: 48-54Siva S. Ali M. Correa R.J.M. et al.

5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).

Lancet Oncol. 23: 1508-1516Correa R.J.M. Louie A.V. Zaorsky N.G. et al.

The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

European Urology Focus. 5: 958-969Mir M.C. Ercole C. Takagi T. et al.

Decline in Renal Function after Partial Nephrectomy: Etiology and Prevention.

J Urol. 193: 1889-1898Mason R. Kapoor A. Liu Z. et al.

The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System.

Urol Oncol. 34: 486.e1-486.e7Siva S. Pham D. Kron T. et al.

Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial.

BJU Int. 120: 623-630Lucas S.M. Stern J.M. Adibi M. et al.

Renal function outcomes in patients treated for renal masses smaller than 4 cm by ablative and extirpative techniques.

J Urol. 179 (): 75-79Wah T.M. Irving H.C. Gregory W. et al.

Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours.

BJU Int. 113: 416-428Sriprasad S. Aldiwani M. Pandian S. et al.

Renal Function Loss After Cryoablation of Small Renal Masses in Solitary Kidneys: European Registry for Renal Cryoablation Multi-Institutional Study.

J Endourol. 34: 233-239Tetar S.U. Bohoudi O. Senan S. et al.

The Role of Daily Adaptive Stereotactic MR-Guided Radiotherapy for Renal Cell Cancer.

Cancers. 12: 2763Siva S. Louie A.V. Warner A. et al.

Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).

Cancer. 124: 934-942Yim K. Cagney D.N. Mak R.H. et al.

Safety and Efficacy of Stereotactic MRI-Guided Adaptive Radiation Therapy for Localized Kidney Cancer.

Int J Radiat Oncol Biol Phys. 114: e207Freifeld Y. Pedrosa I. Mclaughlin M. et al.

Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus.

Urol Oncol. 40: 166.e9Sia J. Szmyd R. Hau E. et al.

Molecular Mechanisms of Radiation-Induced Cancer Cell Death: A Primer.

Front Cell Dev Biol. 8 () ()Wile G.E. Leyendecker J.R. Krehbiel K.A. et al.

CT and MR imaging after imaging-guided thermal ablation of renal neoplasms.

Radiographics. 27 (): 325-339Weight C.J. Kaouk J.H. Hegarty N.J. et al.

Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors.

J Urol. 179 (): 1277-1281Raman J.D. Stern J.M. Zeltser I. et al.

Absence of viable renal carcinoma in biopsies performed more than 1 year following radio frequency ablation confirms reliability of axial imaging.

J Urol. 179: 2142-2145Nadler R.B. Kim S.C. Rubenstein J.N. et al.

Laparoscopic renal cryosurgery: the Northwestern experience.

J Urol. 170: 1121-1125Gill I.S. Novick A.C. Meraney A.M. et al.

Laparoscopic renal cryoablation in 32 patients.

Urology. 56: 748-753Ponsky L. Lo S.S. Zhang Y. et al.

Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma.

Radiother Oncol. 117: 183-187Franzese C. Franceschini D. Di Brina L. et al.

Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma.

J Urol. 201: 70-76Palma D.A. Olson R. Harrow S. et al.

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.

J Clin Oncol. 38: 2830-2838Tang C. Msaouel P. Hara K. et al.

Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.

Lancet Oncol. 22: 1732-1739Staehler M. Bader M. Schlenker B. et al.

Single Fraction Radiosurgery for the Treatment of Renal Tumors.

J Urol. 193: 771-775Chang J.H. Cheung P. Erler D. et al.

Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma in Non-surgical Candidates: Initial Clinical Experience.

Clin Oncol. 28: e109-e114Correa R.J.M. Rodrigues G.B. Chen H. et al.

Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors: A Retrospective Case Series Evaluating Clinical Outcomes, Toxicity, and Technical Considerations.

Am J Clin Oncol. 41: 568-575Kasuya G. Tsuji H. Nomiya T. et al.

Updated long-term outcomes after carbon-ion radiotherapy for primary renal cell carcinoma.

Cancer Sci. 109: 2873-2880Kasuya G. Tsuji H. Nomiya T. et al.

Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma.

Oncotarget. 10: 76-81Senger C. Conti A. Kluge A. et al.

Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.

BMC Urol. 19: 96